Cargando…
Characterization and comparison of human glioblastoma models
Glioblastoma (GBM) is one of the deadliest cancers. Treatment options are limited, and median patient survival is only several months. Translation of new therapies is hindered by a lack of GBM models that fully recapitulate disease heterogeneity. Here, we characterize two human GBM models (U87-luc2,...
Autores principales: | Schulz, Julia A., Rodgers, Louis T., Kryscio, Richard J., Hartz, Anika M.S., Bauer, Björn |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9347152/ https://www.ncbi.nlm.nih.gov/pubmed/35922758 http://dx.doi.org/10.1186/s12885-022-09910-9 |
Ejemplares similares
-
442 Repurposing FDA-approved PI3K/Akt Inhibitors to Improve Anti-Cancer Drug Brain Uptake in Glioblastoma Resection Models
por: Rodgers, Louis, et al.
Publicado: (2022) -
ABCB1 and ABCG2 Regulation at the Blood-Brain Barrier: Potential New Targets to Improve Brain Drug Delivery
por: Schulz, Julia A., et al.
Publicado: (2023) -
ABC Transporters and the Alzheimer’s Disease Enigma
por: Wolf, Andrea, et al.
Publicado: (2012) -
Drug-Resistant Epilepsy: Multiple Hypotheses, Few Answers
por: Tang, Fei, et al.
Publicado: (2017) -
Proteasome inhibition protects blood–brain barrier P-glycoprotein and lowers Aβ brain levels in an Alzheimer’s disease model
por: Vulin, Milica, et al.
Publicado: (2023)